SLXN (Silexion) Net Assets per Single Share

Silexion Therapeutics Corp (SLXN) minimizes capital expenditures by outsourcing the production and testing of RNA drugs to third-party contractors. The fair book value per share reflects asset dynamics, with the indicator currently at 0.04. The company's strategy is based on combating KRAS mutations across various types of cancer, while stability is ensured by a strong team of interference experts.

SLXN (Silexion) Book Value of One Share history from 08/17/2024 to 10/31/2026

Financial and market metric breakdowns for Silexion Therapeutics Corp. (SLXN)

- share price and expert price forecast:
Stock Quotes Silexion|SLXN - Broker Consensus Forecast
- business market valuation indicators:
Market Value Silexion Therapeutics Corp|SLXN - Business Value
- shareholders' equity book value data:
Book Value per Share Silexion Therapeutics|SLXN - Book Value of Business|Market Capitalization to Book Value Ratio silexion.com|SLXN - Company Assets
- debt burden and liquidity indicators:
Debt to Equity Silexion Therapeutics Corp|SLXN - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Silexion|SLXN - Company Cumulative Debt|Debt to Book Capitalization Ratio Silexion Therapeutics Corp|SLXN - Company Long-Term Loans and Borrowings|Company Short-Term Debts Silexion Therapeutics|Quick Liquidity silexion.com
- net income and valuation multiples indicators:
SLXN - Company Net Income
Basic company analysis:SLXN - silexion.com

A conservative approach to analyzing Silexion Therapeutics Corp (SLXN) requires an assessment of the actual net asset value available to each shareholder. The trend in book value per share reflects the difference between total assets and liabilities, which, for the biotech sector, confirms the capitalization of oncology patents and determines the stability of the company's investment profile during the long-term monetization of its developments.

Competing companies

INCY: Accounting Value per Share|HCM (HUTCHMED Corp) - Equity per Share|Nuvation Bio Inc. (NUVB) - Net Assets per Single Share|Equity per Share DAWN|MNPR (Monopar Therapeutics Inc.) - Book Value per Share|INBX - Book Value of One Share|Book Value per Share IMAB|FENC - Net Asset Value per Share|Net Assets per Single Share Heron Therapeutics, Inc. HRTX|NVCT: Equity per Share|Coherus Biosciences - Book Value per Share|Net Asset Value per Share Corbus Pharmaceuticals Holdings, Inc.|cardiffoncology.com (CRDF) - Net Assets per Single Share|BeyondSpring Inc - Accounting Value of a Share|BCAB (BioAtla Inc) - Book Value per Share|Book Value per Share lixte.com|Net Assets per Single Share Citius Pharmaceuticals (CTXR)|Net Assets per Single Share CLRB (Cellectar Biosciences Inc)|BioLineRx Corp - Accounting Value per Share|Accounting Value of a Share CANF|APRE - Net Assets per Single Share|Net Asset Value per Share Kazia Therapeutics|nucana.com (NCNA) - Net Assets per Single Share|Equity per Share CMRX|CYCC (Cyclacel Pharmaceuticals Inc.) - Book Value per Share|Accounting Value per Share G1 Pharma (GTHX)|Net Assets per Single Share Kronos Bio, Inc. (KRON)|KTRA - Net Asset Value per Share|Net Assets per Single Share Oncternal Therapeutics, Inc. ONCT|Portage Biotech Inc - Net Assets per Single Share